NCT02834936View on ClinicalTrials.gov

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

June 20, 2019

Study Completion Date

June 20, 2019

Conditions
Non Small Cell Lung
Interventions
DRUG

pyrotinib

Trial Locations (11)

200433

Shanghai Pulmonary Hospital, Shanghai

Unknown

HR-BLTN-II-NSCLC Investigational Site, Beijing

HR-BLTN-II-NSCLC Investigational Site, Changsha

HR-BLTN-II-NSCLC Investigational Site, Guangzhou

HR-BLTN-II-NSCLC Investigational Site, Hangzhou

HR-BLTN-II-NSCLC Investigational Site, Harbin

HR-BLTN-II-NSCLC Investigational Site, Nanjing

HR-BLTN-II-NSCLC Investigational Site, Shanghai

HR-BLTN-II-NSCLC Investigational Site, Suzhou

HR-BLTN-II-NSCLC Investigational Site, Wuhan

HR-BLTN-II-NSCLC Investigational Site, Zhengzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02834936 - A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation | Biotech Hunter | Biotech Hunter